Editas Medicine (EDIT) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zura Bio (ZURA) has outperformed Editas Medicine (EDIT) over the past year, losing 4.8% versus a loss of 31.6%. Editas Medicine is the larger company by market cap ($445.4 million vs $383.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | ZURA |
|---|---|---|
| Share price | $2.90 | $4.00 |
| Market cap | $445.38M | $383.32M |
| 1-day change | +2.11% | -3.15% |
| YTD return | +38.54% | -21.18% |
| 1-year return | -31.57% | -4.84% |
| 5-year return | -92.53% | — |
| EPS (TTM) | $-0.68 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $7.44 |
| 52-week low | $1.66 | $3.15 |
| Distance from 52-week high | -33.03% | -46.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +103.45% | +350.00% |
| Average volume | 2.51M | 1.44M |
| Shares outstanding | 153.58M | 95.83M |
| Employees | 87 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZURA has outperformed EDIT by 26.7 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
EDIT vs ZURA FAQ
Which is bigger, Editas Medicine or Zura Bio?
Editas Medicine (EDIT) is larger, with a market capitalization of $445.38M compared with $383.32M for Zura Bio (ZURA).
Which stock has performed better over the past year, EDIT or ZURA?
ZURA returned -4.84% over the past 12 months, compared with -31.57% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.